🚀 VC round data is live in beta, check it out!
NewMarket Valuation Multiples
Discover revenue and EBITDA valuation multiples for NewMarket and similar public comparables like Chongqing Zhifei, CRISPR Therapeutics, Caris Life Sciences, SK Biopharmaceuticals and more.
NewMarket Overview
About NewMarket
NewMarket Corp is a holding company that, through its subsidiaries, manufactures and sells petroleum additives used in lubricating oils and fuels to enhance performance. The company operates through two segments: petroleum additives, mainly represented by Afton, where lubricant additives improve the efficiency and durability of base fluids and fuel additives help meet fuel specifications and improve fuel performance, and specialty materials, represented by AMPAC and Calca, including the antiknock compounds business of Ethyl, where primary raw materials include electricity, sodium chlorate, ammonia, chlorine, caustic, and hydrochloric acid, with graphite used in electrolytic cells. The company has operations in North America, Latin America, Asia Pacific, and EMEAI regions.
Founded
2004
HQ
Employees
2.0K
Website
Sectors
Financials (LTM)
EV
$7B
NewMarket Financials
NewMarket reported last 12-month revenue of $3B.
In the same LTM period, NewMarket generated $419M in net income.
Revenue (LTM)
NewMarket P&L
In the most recent fiscal year, NewMarket reported revenue of $3B and EBITDA of $723M.
NewMarket expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $3B | XXX | $3B | XXX | XXX | XXX |
| Gross Profit | — | XXX | $857M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 32% | XXX | XXX | XXX |
| EBITDA | — | XXX | $723M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 27% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 20% | XXX | XXX | XXX |
| Net Profit | $419M | XXX | $419M | XXX | XXX | XXX |
| Net Margin | 15% | XXX | 15% | XXX | XXX | XXX |
| Net Debt | — | — | $806M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
NewMarket Stock Performance
NewMarket has current market cap of $6B, and enterprise value of $7B.
Market Cap Evolution
NewMarket's stock price is $625.33.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $7B | $6B | 0.0% | XXX | XXX | XXX | $44.56 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialNewMarket Valuation Multiples
NewMarket trades at 2.5x EV/Revenue multiple, and 9.4x EV/EBITDA.
EV / Revenue (LTM)
NewMarket Financial Valuation Multiples
As of March 17, 2026, NewMarket has market cap of $6B and EV of $7B.
Equity research analysts estimate NewMarket's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
NewMarket has a P/E ratio of 14.0x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $6B | XXX | $6B | XXX | XXX | XXX |
| EV (current) | $7B | XXX | $7B | XXX | XXX | XXX |
| EV/Revenue | 2.5x | XXX | 2.5x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 9.4x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 12.5x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 7.9x | XXX | XXX | XXX |
| P/E | 14.0x | XXX | 14.0x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 13.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified NewMarket Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
NewMarket Margins & Growth Rates
NewMarket's revenue in the last fiscal year declined by (2%).
NewMarket's revenue per employee in the last FY averaged $1.3M.
NewMarket Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (2%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 27% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (5%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $1.3M | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 5% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 12% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
NewMarket Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Chongqing Zhifei | XXX | XXX | XXX | XXX | XXX | XXX |
| CRISPR Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Caris Life Sciences | XXX | XXX | XXX | XXX | XXX | XXX |
| SK Biopharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Lundbeck | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
NewMarket M&A Activity
NewMarket acquired XXX companies to date.
Last acquisition by NewMarket was on XXXXXXXX, XXXXX. NewMarket acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by NewMarket
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialNewMarket Investment Activity
NewMarket invested in XXX companies to date.
NewMarket made its latest investment on XXXXXXXX, XXXXX. NewMarket invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by NewMarket
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout NewMarket
| When was NewMarket founded? | NewMarket was founded in 2004. |
| Where is NewMarket headquartered? | NewMarket is headquartered in United States. |
| How many employees does NewMarket have? | As of today, NewMarket has over 2K employees. |
| Who is the CEO of NewMarket? | NewMarket's CEO is Thomas E. Gottwald. |
| Is NewMarket publicly listed? | Yes, NewMarket is a public company listed on NYSE. |
| What is the stock symbol of NewMarket? | NewMarket trades under NEU ticker. |
| When did NewMarket go public? | NewMarket went public in 1972. |
| Who are competitors of NewMarket? | NewMarket main competitors are Chongqing Zhifei, CRISPR Therapeutics, Caris Life Sciences, SK Biopharmaceuticals. |
| What is the current market cap of NewMarket? | NewMarket's current market cap is $6B. |
| What is the current revenue of NewMarket? | NewMarket's last 12 months revenue is $3B. |
| What is the current EV/Revenue multiple of NewMarket? | Current revenue multiple of NewMarket is 2.5x. |
| Is NewMarket profitable? | Yes, NewMarket is net-income-positive (as of the last 12 months). |
| What is the current net income of NewMarket? | NewMarket's last 12 months net income is $419M. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.